Bay 3771249

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

25 competitors in Colorectal Adenocarcinoma

#DrugCompanyPhaseTrials

1

Afinitor

Novartis

Approved

—2

Levulan

Sun Pharmaceutical Industries, Inc.

Approved

—3

Thalomid

Bristol-Myers Squibb

Approved

—4

Eloxatin

Teva

Approved

—5

Taxol

Teva

Approved

—6

Fudr

Pfizer

Approved

—7

Gleevec

Novartis

Approved

—8

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

19

Decadron

AAspen Global Incorporated

Approved

—10

E-Mycin

AAzurity Pharmaceuticals

Approved

—Show 15 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Colorectal Adenocarcinoma1 trial

Master Protocol: An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BAY 3771249 as Monotherapy or Combination With Other Cancer Treatments in Participants With Solid Tumors Harboring a KRAS G12D Mutation. Substudy Protocol: An Open-label, Multi-cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of BAY 3771249 as Monotherapy and in Combination With Cetuximab in Participants With Advanced/Metastatic Colorectal Adenocarcinoma Harboring a KRAS G12D Mutation

Recruiting·Bayer·Phase 1·NCT07535112·130 enrolled

Details

Drug Info

Related News